This summer, for the 42nd year, professionals from around the world will convene at Georgetown University for an immersive bioethics symposium covering both foundational and emerging topics in the ethics of health, the environment, and emerging technologies.
The Institute’s Intensive Bioethics Course (IBC) offers a diverse cohort of doctors, nurses, dentists, policy-makers, hospital chaplains, lawyers, IRB panelists, and others an opportunity to grapple with some of the most profound moral issues they confront in their work, guided by internationally-renowned bioethics scholars from the KIE and beyond.
With registration for this year’s course open, we thought we’d share some participant reactions to last year’s run for a taste of what this year’s attendees can expect. Comments are drawn from anonymous evaluations offered at the end of IBC41 in June 2015.
On the Bioethics Research Library:
The Bioethics Research Library has nothing less than an exquisite collection or books; I loved browsing the old and new titles on aging and ethics; death; genetic counseling, medical humanities, and (nice to observe that you honor a grand founding father of medical ethics) the recognition of Dr. Pellegrino’s legacy through prominent display of his books and those about him.
The faculty/staff of the library were no less than fabulous. [In the library] I developed experience with crossing the MeSH terms in the NCBI / PubMed database with the bioethics subset. Through one-on-one consultation with Martina Darragh I developed first-hand experience; Martina Darragh is a one-of-a-kind resource to be enormously appreciated.
On our one-on-one research consultations:
Fabulously helpful, as I have effusively expressed to Martina Darragh (and above). I make
mention of Roxie France-Nuruddin, as she may have changed my activities for the upcoming two years and Martina and Roxie, as am I, are excited about lifelong learning in general, and ethics and the history of medicine in particular.
On the small group experience:
The small group meetings were enjoyable and I, among others in my group, looked forward to
these meetings — their stimulation, challenging cases, and probing questions — with much anticipation. As a point of pride, I note that my (our?) group was quite exceptional — a blunt reminder of how many smart, insightful and eloquent people there are in the world.
Our small group was led by Maggie Little — she has broad interests and knowledge of public health, drug trials, FDA mechanisms of drug approval, the paths of Phase 1-4 drug trials, reproductive medicine and research ethics (and of course Kant). I couldn’t ask for a more ideal Small Group leader and, indeed, it was my hope when I registered that Maggie would be leading the group I was assigned to. Aside from her resonant intellect, Maggie Little is an intent listener, a quality allowing her to provide focus to the discussion and to further extend it.
On the impact of the course:
It will contribute to my teaching of medical students and pharmacy (PharmD) students. Also, it provides a further foundation for developing case studies in the ethics of drug treatment of, for example, mental illness and pain syndromes, and public policy during public health emergencies.
This was a fabulous course. I valued the opportunities to meet the faculty, to have benefit of
working with Maggie Little and Laura Bishop and Martina Darragh. The week was virtually flawless.